Isolariciresinol

CAS No. 548-29-8

Isolariciresinol( —— )

Catalog No. M30997 CAS No. 548-29-8

(+)-Isolariciresinol is extracted from Radix Isatidis and shows antioxidant and anti-inflammatory activities and can be used in studies about rheumatism.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 302 In Stock
5MG 282 In Stock
10MG 443 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Isolariciresinol
  • Note
    Research use only, not for human use.
  • Brief Description
    (+)-Isolariciresinol is extracted from Radix Isatidis and shows antioxidant and anti-inflammatory activities and can be used in studies about rheumatism.
  • Description
    (+)-Isolariciresinol is extracted from Radix Isatidis and shows antioxidant and anti-inflammatory activities and can be used in studies about rheumatism.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    548-29-8
  • Formula Weight
    360.4
  • Molecular Formula
    C20H24O6
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Columbamine

    Columbamine exerts anti-proliferative and anti-vasculogenic effects on metastatic human osteosarcoma U2OS cells with low toxicity.

  • Lomibuvir

    Lomibuvir (VCH-222) is a selective, non-nucleoside allosteric inhibitor of HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC 50 of 5.2 nM.

  • BC-1382

    BC-1382 is a potent ubiquitin E3 ligase HECTD2 inhibitor that specificly disrupts the HECTD2/PIAS1 interaction(IC50 of 5 nM).BC-1382, that targeted HECTD2 and attenuated lipopolysaccharide (LPS)- and Pseudomonas aeruginosa-induced lung inflammation.?